<DOC>
	<DOC>NCT03069365</DOC>
	<brief_summary>This Phase 3b, open-label, non-randomized study will evaluate the efficacy and safety of Glecaprevir/Pibrentasvir (GLE/PIB) for 8, 12, or 16 weeks in in participants with chronic hepatitis C virus (HCV) genotype (GT) 1 - 6 infection with or without compensated liver cirrhosis and with chronic renal impairment in both HCV treatment-naïve and prior treatment-experienced participants.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Participant has a positive antihepatitis C virus (HCV) antibody (Ab) and plasma HCV ribonucleic acid (RNA) greater than or equal to 1000 IU/mL at Screening Visit. Participant has an estimated glomerular filtration rate (eGFR) less than 45mL/min/1.73 m^2 Cirrhotic participants only: absence of hepatocellular carcinoma (HCC) Current HBV or human immunodeficiency virus (HIV) infection on screening tests, defined as: Positive test result at screening for hepatitis B surface antigen (HBsAg) or HBV DNA less than lower limit of quantification (LLOQ) in participants with isolated positive antiHBc (i.e., negative HBsAg and AntiHBs), or Positive antiHIV antibody (Ab). Clinical history of acute renal failure in the 3 months prior to screening. Clinically significant abnormalities or comorbidities, or recent (within 6 months prior to study drug administration) alcohol or drug abuse that could preclude adherence to the protocol in the opinion of the investigator. Receipt of any investigational or commercially available direct acting antiHCV agents other than sofosbuvir.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ribavirin (RBV)</keyword>
	<keyword>non-cirrhotic</keyword>
	<keyword>treatment naïve</keyword>
	<keyword>interferon (IFN)</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Hepatitis C Virus Genotype</keyword>
	<keyword>Chronic Hepatitis C Virus</keyword>
	<keyword>compensated cirrhosis</keyword>
	<keyword>pegylated interferon (pegIFN)</keyword>
	<keyword>sofosbuvir (SOF)</keyword>
	<keyword>Glecaprevir</keyword>
	<keyword>Pibrentasvir</keyword>
</DOC>